O-1871

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
O-1871
280px
Systematic (IUPAC) name
2-(3,3-dimethylcyclohexyl)-5-(2-methyloctan-2-yl)benzene-1,3-diol
Clinical data
Legal status
  • Banned as cyclohexylphenol derivative (US, UK)
Identifiers
CAS Number 620964-96-7
ATC code none
PubChem CID: 10405368
ChemSpider 8580806
Chemical data
Formula C23H38O2
Molecular mass 346.55 g/mol
  • CC(C1)(C)CCCC1C2=C(O)C=C(C(C)(C)CCCCCC)C=C2O
  • InChI=1S/C23H38O2/c1-6-7-8-9-13-23(4,5)18-14-19(24)21(20(25)15-18)17-11-10-12-22(2,3)16-17/h14-15,17,24-25H,6-13,16H2,1-5H3
  • Key:WBSPBIRKSHKQQD-UHFFFAOYSA-N

O-1871 is a potent cannabinoid agonist which was invented by Billy R Martin and Raj K Razdan in 2002. It has a CB1 receptor affinity of 2.0nM and a CB2 receptor affinity of 0.3nM.[1] Structurally, O-1871 is a cyclohexylphenol derivative related to CP 47,497, and so is illegal in most jurisdictions where CP 47,497 and its derivatives are banned. However the 3,3-dimethylcyclohexyl substituent of O-1871 can be replaced by various other groups, producing other potent compounds such as the cycloheptyl derivative O-1656 and the 2-adamantyl derivative O-1660, as well as the corresponding 3,5-dichlorophenyl derivative,[2] which are not cyclohexylphenol derivatives.

See also

References

<templatestyles src="Asbox/styles.css"></templatestyles>